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INTRODUCTION
Teratomas are the most common germ cell tumors in children
and are classified as mature (MT), immature (IT), and malignant.
IT contain neuroectodermal or blastemal tissue, the relative
amount of which is scored according to a grading system
introduced by Norris, modified by Gonzales–Crussi [1,2] and
others [3,4]. Teratomas have a heterogeneous epidemiological,
clinical, and pathological pattern in childhood and adolescence,
relating to a different biological behavior of the disease.
Teratomas develop from totipotent primordial cells, which have
partly lost their genomic imprinting. MT is more frequent than IT;
sacrococcygeal teratoma (SCT) occurs mainly in newborns and
infants, with a female predominance; testicular teratoma (TT) in
the first five years of life, and ovarian teratoma (OT) in older
children up to 15 years of age [5,6]. Both the mature and the
immature components are non-malignant tissues, and their
metastatic potential is uncertain [2]. Despite the benign
histological appearance of these lesions, there will be a small
group of patients whose prognosis might be fatal [7].
Malignant cells can occur as other histological germ cell
subtypes (semonoma, choriocarcinoma, embryonal carcinoma, and
usually yolk sac tumor [YST] in children, or variable combination
of these entities), or as a somatic differentiation called teratoma
with a malignant somatic component (TMSC) [8]: in all such cases,
it is the malignant tissue that decides the type of treatment. MT and
IT usually demonstrate a benign clinical behavior, but they may
recur with a malignant component or as a teratoma.
After the first Italian study [9], we developed guidelines for the
treatment of teratoma, in conjunction with the second national
prospective AIEOP (Associazione Italiana Ematologia Oncologia
Pediatrica) study for malignant germ cell tumors, called the
TCGM2004. A prospective collection of patients’ data was
activated, for the purpose of assessing prognostic factors, type of
relapse and outcome.
PATIENTS AND METHODS
Patients with newly-diagnosed teratoma were collected from
March 2004 to January 2014. The guidelines for teratoma had the
approval of Ethical Committee. Central pathology review was
available, but not mandatory and 153 out of 219 (70%) were
reviewed. Teratomas were classified according to the WHO
classifications, as MT if they were characterized by differentiated
tissue, IT if they contained immature, non-malignant tissues.
Since IT could contain varying amounts of neuroectodermal or
blastemal tissues, they were scored using a grading system
introduced by Norris et al., modified by Gonzales–Crussi and
others [1–4].
Initial diagnostic investigations, including medical history,
physical examination, radiographic studies, histology, description
of surgical specimen, serum levels of alpha fetoprotein (aFP), and
beta human chorionic gonadotropin (bHCG) were collected. In
infants, serum aFP levels were monitored until they reached the
normal value for the general population [10]. Patients with
pathological serum levels of aFP and/or bHCG, and those with a
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malignant germ cell component, including those with microscopic
foci of YST, were not considered in the present analysis. Radiology,
physical examination, and aFP were repeated every 3 and 4 months,
respectively, in the first and second years after surgery, then every
6 months until the 5th year.
Primary surgical resection was the treatment indicated for all
patients. The excision was considered complete (CS) if the teratoma
had been resected in toto, with free margins according to the
pathology report and no residual disease or rupture, or microscopi-
cally or macroscopically incomplete (IS), in the light of the
pathology report and the surgeon’s description. In cases of tumor
rupture, the excision was defined as microscopically incomplete.
Surgical biopsy was to be performed if excision of the mass was
judged unfeasible. There were specific guidelines for OT, TT, SCT,
and mediastinal teratoma. For OT, the surgical approach was via a
transversal, subumbilical incision or a Pfannestiel incision as
follows: excision of the tumor together with the ovary, preserving
the salpinx, if possible; inspection of the contralateral ovary, biopsy
of suspected areas or regional lymph nodes, peritoneal fluid
sampling or washing for cytology. For TT, an inguinal orchifuni-
culectomy was recommended after clamping the spermatic cord.
Complete en-bloc resection of the coccyx was mandatory for SCT.
The guidelines contained no recommendations on laparoscopic
procedures for ovarian masses and/or conservative surgery for
TT: all these cases were collected nonetheless. The disease was not
up-staged in the event of gliomatosis peritonei. Overall survival
(OS), relapse-free survival (RFS) and event-free survival (EFS)
rates were analyzed using the Kaplan–Meier method [11]. A
logistic regression analysis was performed considering type of
surgery (CS, IS), site of disease (OT, TT, SCT, other extragonadal T)
and teratoma grade.
RESULTS
The study involved 219 patients, that is, 150 with MTand 69 with
IT, with a median age at diagnosis of 42 months (range 0–20.4 years).
The patients’ main characteristics are listed in Table I. Centralized
pathology review was done for 70% of patients, and the diagnosis
was consistent in 95% of cases: the discrepancies mainly concerned
MTwith microscopic foci of immaturity being changed to IT grade I,
IT grade II changing to grade III, and vice versa, and teratomas with
microscopic foci of YST. There was a female prevalence of teratoma
(F:M¼ 2.5:1) and the primary sites involved were: 95 OT, 23 TT, and
101 extragonadal teratomas (ET). Eleven patients (5%) had
associated congenital malformations or syndromes (Table II).
Mature Teratoma
MT accounted for 68.5% of the whole series, with a median age
of 55 months. We observed 68 OT, 63 ET, and 19 TT. Two patients
developed other malignancies, a synchronous medulloblastoma and
a metachronous adrenal neuroblastoma; both tumors were removed
completely and the two patients were alive and relapse-free at the
time of writing. Two patients with OT had a family history of OT in
the mother.
CS were obtained at diagnosis in 133 patients (89%), and IS in 8
(5%). This information was unavailable for nine cases. One patient
with SCT obtained a CS after two successive surgical procedures.
One of two females with synchronous bilateral OT underwent
bilateral enucleation, the other had oophorectomy and enucleation.
Of 66 females with unilateral OT, seven had tumor enucleation (5
using a laparoscopic procedure), and two had laparoscopy and
oophorectomy. The remainder (87%) had oophorectomy according
TABLE I. Patient Characteristics
MT (150) IT (69) Total
Sex F/M 109/41 48/21 157/62
Age
Range (years) 0–20.4 0–15.2 0–20.4
Median (months) 55 7 42
Primary site of T
Ovary 68 27 95
Testis 19 4 23
Extra 63 38 101
Sacrococcyx 40 25 65
Mediastinum 8 4 12
Retroperitoneum 6 4 10
Other site 9 5 14
T grading
Not done 4 testesþ 4 ET
1 25 25
2 25 25
3 11 11
Surgery
Complete 133 54 187
Incomplete 8 11 19
Unknown 9 4 13
Relapse 3 8 11
Exitus 0 2 2
Lost to follow-up 4 3 7
Metachronous OT 4 1 5
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to the surgical guidelines. Orchifuniculectomy was performed in 12
males, and 7 (37%) had tumor enucleation with preservation of the
residual testicular tissue. One male in this last group was monorchid
at birth. No cases of bilateral TT were recorded.
Second tumors and relapses. Eight events were observed
(4.6%): four of the 66 patients with OT had contralateral
metachronous OT, detected after 11–84 months of follow-up; they
were managed by means of sparing surgery in three and ovariectomy
in one. One female had a metachronous adrenal neuroblastoma. All
these patients were alive and relapse-free at the time of writing.
Three ET relapsed with YST and/or an increase in aFP, two of whom
had undergone CS at diagnosis. One SCT with a recurrence in the
vertebral canal was treated with two different platinum-based
chemotherapy regimens to maximize response, without further
surgery. A patient with head and neck teratoma had a biopsy at the
time of relapse, followed by chemotherapy, with a normalization of
the pathological aFP levels, and there was no evidence of vital tumor
at subsequent surgery on the residual mass. The last patient was a
female with an increased aFP and local and lung metastases. After
biopsy she underwent cisplatin-based chemotherapy, and her aFP
levels returned to normal, with complete remission of metastases,
and partial remission of the presacral lesion, without further surgery.
All three patients were alive, while two had stable disease after
relapsing 10 and 115 months. The main clinical characteristics of the
patients who relapsed are listed in Table III.
Immature Teratoma
Sixty-nine patients (31.5%) had IT at a median age of 7 months.
There was a prevalence of extragonadal sites (55%), with 38 ET, 27
OT, and 4 TT. For 8/69 cases (11.6%), information on tumor grading
was unavailable (because four were cases of TT [12], and the local
pathologist had not graded the lesions in another four); among the
other 61 IT, 25 were grade 1 (G1), 25 were grade 2 (G2), and 11
were grade 3 (G3).
Three patients had TMSC at diagnosis (Table II), one at relapse.
The first three cases included one with a microfocal area of
carcinoma, one with a microfocal area of medulloepethelioma (for
which CS was the only treatment administered), and one male with
Currarino syndrome and SCT G2 with multiple foci of carcinoma.
After IS this male was administered a cisplatin-based chemothera-
py. All patients were alive and relapse-free with a median time of
follow-up of 36 months.
CS and IS were obtained at diagnosis in 54 patients (78%) and
11 patients (16%), respectively, while no information was available
on four cases. Two patients with SCT achieved a CS after two
successive surgical procedures, and one patient underwent biopsy
for a mediastinal mass followed by a CS.
There were three OTwith gliomatosis peritonei (1 G3, 1 G2, and
1 G1), and three patients with OT G1 had tumor spillage: one of
these during a laparoscopic enucleation. None of the OT with
gliomatosis or tumor spillage relapsed. Of the 27 females with OT, 2
were treated with a laparoscopic procedure (1 oophrectomy and 1
tumor enucleation). The remainder (92.6%) had oophorectomy
according to the surgical guidelines.
Orchifunilectomy was performed in all four patients with TT;
there were no cases of bilateral TT. Chemotherapy was adminis-
tered at the discretion of treating physician in 4 cases.
Second tumors and relapses. Nine patients (13%) experi-
enced an event: eight teratomas relapsed, and one patient had a
contralateral metachronous ovarian MT. In this last case, the tumor
was detected after 36 months of follow-up; it was managed by
means of sparing surgery and the patient was alive and relapse-free.
Any relapse or progression was always local: four teratomas
relapsed with malignant YST and/or an increase in aFP, and four
with a teratomatous component alone. CS at the time of diagnosis
TABLE II. Associated Syndrome
Site of teratoma Gender Age at diagnosis
Mature teratomas
1 Down syndrome retroperitoneal M 4 mos
1 Down syndrome adrenal cavity F connatal
1 partial deletion of chromosome 1 SC F connatal
1 three rays left hand agenesia SC F connatal
1 coccyx agenesia SC F connatal
1 monorchid testis M 16 mos
1 interventricular shunt ovary F connatal
1 synchronous medulloblastoma ovary F 21 yrs
2 cases of mother with the same disease ovary F 14/11 yrs
1 metachronous neuroblastoma SC F connatal
Site of Teratoma Grade Gender Age at diagnosis
Immature teratomas
1 Currarino syndromea SC 2 M 22 mos
1 lower limb congenital ectromelia ovary 2 F 12 yrs
1 congenital hypothyroidism SC 3 M connatal
1 tricuspid valve atresia SC 2 F 17 mos
1 TMSC (diffuse carcinoma)a SC 2 M (pt with Currarino S.) 22 mos
1 TMSC (1 microfocal localization of carcinoma) SC 2 F connatal
1 TMSC (1 microfocal localization of medulloepithelioma) ovary 3 F 14 yrs
SC, sacrococcyx; TMSC, teratoma with malignant somatic component. asame patient.
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were 2 in the 54 patients whose primary resection had been
complete, and incomplete in 6 of the 11 patients whose primary
surgery had been IS. All but one of these eight patients had ET, that
was graded as follows: 1 G1 (4%); 4 G2 (16%), and 3 G3 (27%).
Among the malignant relapses, one female with OT revealed a
pathological increase in aFP levels associated with a pelvic mass.
She underwent complete excision of the recurrent tumor and aFP
levels returned to normal. She was administered 2 cycles of
cisplatin-based chemotherapy, with a follow up of 80 months after
the relapse. Two other patients with SCT who experienced a
pathological increase in their aFP levels and a presacral lesion were
given platinum-based chemotherapy and surgery on the residual
disease. One female with pathologically high aFP levels had
multiple local relapses near the rectum: she was administered three
different chemotherapy regimens and one attempt at surgery [13],
which resulted in an IS and rapid tumor re-growth. A last attempt
was made with radiotherapy, obtaining complete remission of the
disease, with a follow up of 38 months after the relapse.
In the group that had exclusively teratomatous relapses, a SCT G2
relapsed after 7 months. The disease was treated with surgery and MT
was found. There were 2 SCT G3 teratoma with multiple relapses. The
first patient was a female with diagnosis at the age of 11 months who
had microscopic residual disease after surgery. The teratoma relapsed
showing the same histology that was partially removed. She underwent
cisplatin-based chemotherapy, but 23 months later the tumor relapsed
locally. After multiple relapses, and distant spread to the lungs, she died
of progression 70 months from diagnosis. The second patient was a
male whose teratoma was diagnosed at the age of 4 years. The tumor
was removed leaving microscopic residual disease, that relapsed
locally with peritoneal implants. After IS and platinum-based
chemotherapy, the teratoma relapsed twice more, with two further
attempts at surgery. Given his multiple peritoneal implants and the
increasing neuroectodermal component, this was considered a TMSC
with PNET transformation. The male was therefore treated according
to the PNET protocol with chemotherapy and radiotherapy to the
whole abdomen. He was alive and relapse-free at the time of writing.
The last patient in this group was a male who underwent partial
resection of a retrobulbar IT G2 followed by platinum-based
chemotherapy, which was stopped after 2 cycles due to tumor
progression with a decline in aFP to normal levels for the patient’s age.
Another attempt at surgery was made but the infant died of surgical
complications. Two out of 69 patients (2.9%) died, one of progressive
disease and one of surgical complications. The main clinical
characteristics of the patients who relapsed are listed in Table III.
All six patients with metachronous tumors were alive and relapse-
free. Of the 11 patients who experienced a disease relapse, 7 were alive
and in complete remission, 2 patients with IT died (one of progressive
disease and the other of surgical complications), and 2 patients with
MT were alive with stable disease but normal aFP levels, 115 and
10 months after relapsing. With a median follow-up of 68 months
(range 0–153 months), the EFS, RFS, and OS rates were: 90.6%,
94.3%, 98.6%. Figures 1–3 show the survival rates for whole series,
MTand IT. The only factor of statistical significance emerging from the
logistic regression was IS in the series as a whole (P¼ 0.015;
CI 1.45–25.94) and in IT group (P¼ 0.04; CI 1.18–39.42).
DISCUSSION
The novel insights generated by our data concern: the need to set
up guidelines for the appropriate use of laparoscopy and
organ-sparing surgery in OT; the need for a prolonged follow-up
due to the risk of contralateral OT, and the consequent use of
available fertility-preserving techniques; the emerging evidence of
familial forms that should be collected and studied.
The series of teratomas described here was registered after
patients had been referred to pediatric surgery centers. It reveals an
increase in the number of cases by comparison with our first study.
Some of the findings reported here are consistent with other reports
and already well known [5,7,14–17], i.e., the female and SC
predominance, the ovarian localization seen in adolescents, the
bimodal age distribution, and the association with congenital
malformations and/or chromosomal syndromes. Our results
confirm previous reports of a good overall survival rate for
teratoma [5,7,9,14–16]. Efforts have been made to use chemother-
apy as an adjuvant strategy for high-risk teratomas [9,15,18], but the
fundamental role of surgery as the gold standard is clear, and it is
often the only treatment approach possible [5,14,16,19,20]. Patients
in our series with microfocal TMSC and CS were given no
additional therapies and, despite the limited number of patients
involved, this result would give the impression that surgery alone
might suffice in this subset of patients too.
There were no relapses or deaths among patients with TT. To
preserve gonadal function in patients whose aFP and bHCG levels
are within normal range, we recommend considering the
conservative approach, where technically feasible.
Fig. 1. Relapse-free survival after mature or immature teratoma, and in
the whole series.
Fig. 2. Event-free survival, relapse-free survival, and overall survival
after mature teratoma.
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There were no deaths among OT patients. None of the OT with
gliomatosis in our series relapsed: this finding is of interest because
there have been reports of this condition being associated with a
higher risk of relapse [5]. Larger series will need to be assessed to
shed light on this issue. The use of laparoscopy is increasing, but its
proper use in childhood ovarian tumors needs to be standardized
(i.e., tumor dimension, cystic component) [5,19,21]. It is important
to avoid the risk of tumor spillage and rupture, and the consequent
up-staging of the disease. Conservative surgery to preserve gonadal
function might be considered, where technically feasible, but only
in patients whose aFP and bHCG levels are within normal range.
Bilateral metachronous OT was seen in five patients, representing
5.2% of the whole series of OT. Although this percentage is low, this
possibility is worth bearing in mind when scheduling patient
follow-up. The risk of bilaterality is already known and ranges from
10 to 23% in women of all ages [22,23]. In our sample, the timing of
the diagnosis of contralateral tumors ranged between 11 and
84 months, but the interval could be even longer. A three-year
follow-up has been suggested for teratoma at any site [7,19,22]. It
may be wise to extend the follow-up for females with OT given the
risk of contralateral tumor, or to recommend regular yearly pelvic
ultrasound throughout their fertile lives. The estimated growth rate
of MT is slow, and the goal of repeated ultrasound is to preserve
fertility [22]. Conservative ovarian surgery should be the standard
indication for females for whom fertility is an important issue. To
make this option possible, it is mandatory to ensure the viability of
the remaining ovarian tissue without running the risk of incomplete
tumor removal. Another possible option in these rare circum-
stances, depending on the patient’s age, is to consider fertility
preservation counseling.
Although MT are some of the most common ovarian neoplasms
in females younger than 20 years of age, familial cases are very rare.
Nezhat et al. [24] described a familial cystic ovarian teratoma and
reviewed other familial cases (sisters, twins, mother, and
daughters). The hypothesized pathogenesis implies a genetic
defects that could be transferred from one generation to the next,
giving rise to an increased risk in the same family [25]. All these
findings point to the importance of collecting these data and
gathering an exhaustive family medical history.
Survival rates show that the group with IT plus IS was more
likely to recur. It has been reported that the risk of recurrence is
higher for cases of IS, immature elements, and for SCT, than for
gonadal sites. [5,7,9,15,20,26]. In the present series, the only
statistically significant factor for relapse was IS in the series as a
whole and in the IT group. The limitation of this study is that some
of the findings reported here are consistent with other reports and
already well known. The importance of CS is well-documented, and
in some cases it is hard to achieve this without mutilating surgery.
Nevertheless, it is important to ensure that all pediatric surgeons are
well aware of the relevance of CS and, whenever possible, to
suggest for a subsequent radical surgery. The present and previous
Italian studies [9] identified much the same percentages of cases of
IS (9% vs. 10%), and of patients among them who relapsed (37% vs.
35%), confirming the high risk of relapse in this subset of patients.
For all these reasons, it is important to perform follow up exams in
patients with teratomas, but especially those incompletely resected
with IT. In cases with a malignant germ cell component, aFP is an
early sign of relapse, and testing aFP levels may help to reduce the
burden of follow-up.
The standard treatment for relapse (surgery for teratoma and
platinum-based chemotherapy for malignant germ cell compo-
nents) was effective, but with some exceptions. For the rare
condition of TMSC, the pathologist’s expertise is fundamentally
important in helping clinicians to choose the optimal treatment.
There are no typical clinical or radiological signs to predict TMSC,
which is one of the reasons why surgery or biopsy are advocated for
patients without evidence of elevated tumor markers. In cases of
multiple relapses with an aggressive behavior, transformation is a
possibility to consider.
Another critical issue is the management of the disease with no
evidence of malignant component [18]. In 1982 Gonzalez–Crussi
reported on the risk of IT being classified as benign, but
subsequently becoming metastatic [2]. Progressive tumor growth
can prove fatal if surgery is not feasible because teratomas are
scarcely sensitive to chemotherapy and radiotherapy. For a case of
growing teratoma (GT) syndrome [28], in which surgery is not an
option, it has been suggested that an attempt be made with four
agent-drug combinations with an antiangiogenetic potential, as well
as low-dose chemotherapy [29]. Whatever the underlying mecha-
nism, and despite their biological diversity, teratomas, and GT
syndromes share much the same therapeutic problems, since both
are unresponsive to chemotherapy. On these grounds, an attempt at
individual treatment with an antiangiogenetic potential might be
worthwhile. For the time being, no effective drugs are currently
available and an international effort would be helpful.
In conclusion, patients with teratoma have good survival rates and
there appears to be no need for further treatment after surgery. ITwith
IS are at higher risk of relapse than those with MT (with or without a
malignant component). New approaches are needed to deal with this
last condition that, though rare, may sometimes be fatal. Several
novel findings emerge from this study concerning: the feasibility of
omitting chemotherapy even for patients with TMSC with CS; the
lack of appropriate guidelines for the use of laparoscopy in pediatric
patients; the need for a protracted follow-up due to the risk of
contralateral OT (with a view to avoiding fertility-related con-
sequences in young females); and a rare family predisposition for
mature OT that warrants further analysis.
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